TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02757404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasonography guidance injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrical stimulation guidance injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manual needle placement injection of Meditoxin®.
Description: Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
Study: NCT01526317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
Study: NCT04672070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selective Caries Removal
Description: Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses.
Study: NCT01820767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol, atorvastatin
Description: Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
Study: NCT02049229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: Optimax-stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Synergy stent implantation
Study: NCT02315105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Greater Curvature Plication
Description: LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
Study: NCT01960504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (DREAMS) stenting
Study: NCT02802956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Life Promotion Program
Description: Daily Life Promotion Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general rehabilitation treatment
Description: general rehabilitation treatment
Study: NCT03799627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Vadadustat Tablets 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin Alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat TIW
Description: Oral Vadadustat
Study: NCT04148768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inferential therapy
Description: Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short wave diathermy
Description: SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
Study: NCT03571113

Intervention type: OTHER
Intervention: Survival / not survival
Description: Outcome with good neurological status vs. bad neurological status at hospital discharge

Intervention type: OTHER
Intervention: Survival / not survival
Description: Outcome with good neurological status vs. bad neurological status at hospital discharge
Study: NCT03975530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision Family Spirit
Description: Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Family Spirit
Description: Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
Study: NCT02253472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study: NCT02244658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
Study: NCT03039569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages
Study: NCT00963937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 25 mg
Description: One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 50 mg
Description: Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Study: NCT02801396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)
Study: NCT04260555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1601
Description: Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW16011
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
Study: NCT02801396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 1 (Test 1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)
Study: NCT04260555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW16012
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
Study: NCT04597632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brolucizumab
Description: brolucizumab 6 mg/0.05 mL solution for intravitreal injection
Study: NCT02938559

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy (CT) for depression
Description: There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
Study: NCT02801396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)
Study: NCT02938559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) for depression + Memory Support
Description: The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Study: NCT00723723

Intervention type: DRUG
Intervention: Statin
Description: Statin
Study: NCT04111055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: the CLV system will correct hypotension by automated adjustment of norepinephrine.
Study: NCT02801396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A Design 2 (Test 2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A (Control)
Study: NCT02740881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselor Training Methods
Study: NCT02646852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX038
Study: NCT02740881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselor Training Methods
Study: NCT02083783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRI102
Description: formulation containing active moiety (amphetamine)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: formulation without active moiety
Study: NCT04179708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on).
Study: NCT02675439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-S100
Study: NCT04179708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional education
Description: assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional education
Description: assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it).
Study: NCT06508398

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological Diagnostic Testing
Description: This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs.
Study: NCT04080375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patient will take one vaginal tablet of placebo 1 hour before surgery
Study: NCT01375244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Tablets, 10 mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestril
Description: Tablets, 10 mg, single dose
Study: NCT03962842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates method
Description: The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
Study: NCT04486105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet
Study: NCT01279967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: 36.8mg/m2 based on BSA, weekly treatment for 6 months
Study: NCT02675439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study: NCT04226326

Intervention type: OTHER
Group type: OTHER
Intervention: Directly measure microvascular function using direct coronary flow measurements
Description: The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
Study: NCT01339780

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BS, SPECT/CT, PET/CT, MRI
Description: Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BS, SPECT/CT, PET/CT, MRI
Description: Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
Study: NCT04486105

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: pure sucrose in water in addition to habitual diet